newsfilter
← Latest News
GlobeNewswire·

PetVivo, a Leading Provider of Veterinary Biomedicals, Reports Results for Fiscal Q1 2027

PETV
  • PetVivo Holdings reported fiscal Q1 2027 results for the period ended June 30, 2026, with revenues of $337,572 \& a net loss of $1,738,888 available to common stockholders.
  • The company announced the acquisition of PiezoBioMembrane (PBM) to combine patented piezoelectric technologies with PetVivo's commercial capabilities, subject to closing conditions.
  • PetVivo.ai expanded its beta program with select clinics, achieving a 50%-90% reduction in customer acquisition costs to under $43 \& demonstrating 97% diagnostic accuracy for conditions like osteoarthritis.
  • R\&D progress on the three-part program with PBM completed Stage B, confirming scalable production \& preliminary safety for combined biomaterials, while Stage C safety \& efficacy studies are underway.
  • The company strengthened its sales team by appointing Jennifer Douglas as the Texas field territory manager, with additional regional hires planned for the Midwest \& Southwest.
  • New canine \& equine studies on Spryng® efficacy \& tolerance are being developed for peer-reviewed publication, including analysis of data from the Orthobiologic Innovations pilot study.
  • PetVivo advanced its product pipeline to include functional biomaterials \& tissue-mimicking structures, with plans to pursue FDA clearance for human applications incorporating PBM technology.
  • The company exhibited Spryng® at the International Veterinary Academy of Pain Management Forum \& continued training initiatives with the Veterinary Growth Partners network.
  • Subsequent events included the publication of a peer-reviewed study in Veterinary Record, exhibition at the Texas Equine Veterinary Association symposium, \& the conclusion of the commercial partnership with VetStem.
  • PetVivo filed for a federal government grant with PBM \& the University of Connecticut to fund five high-value technologies, with a decision expected by year-end.
  • Management highlighted a new exclusive white-label licensing agreement with Digital Landia for AgenticPet technology \& the launch of a data monetization framework for PetVivo.ai.
  • The company plans to introduce the PetVivo.ai SaaS platform to the market within the next few months, targeting high gross margins \& recurring revenue streams.
  • PetVivo CEO John Lai emphasized the company's focus on high-margin recurring revenue, strategic M\&A, \& leveraging the projected doubling of the U.S. animal health market to $11.3 billion by 2030.